Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
Appl Health Econ Health Policy
.
2022 Jul;20(4):623.
doi: 10.1007/s40258-022-00734-z.
Authors
Sara Stafford
1
,
Peter G Bech
2
,
Adam Fridhammar
3
,
Nino Miresashvili
4
,
Andreas Nilsson
3
,
Michael Willis
3
,
Aiden Liu
2
Affiliations
1
Fraser Health Division of Endocrinology, 902-13737 96th Avenue, Surrey, BC, V3V 0C6, Canada. sara.stafford@fraserhealth.ca.
2
Novo Nordisk Canada Inc., 2476 Argentia Rd, Mississauga, ON, L5N 6M1, Canada.
3
The Swedish Institute for Health Economics, Box 2127, 220 02, Lund, Sweden.
4
Novo Nordisk A/S, Vandtårnsvej 108, 2860, Søborg, Denmark.
PMID:
35441978
PMCID:
PMC9206918
DOI:
10.1007/s40258-022-00734-z
No abstract available
Publication types
Published Erratum